Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jul;64(1):124–127. doi: 10.1038/bjc.1991.254

The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer.

I M Muir 1, R G Reed 1, S A Stacker 1, A I Alexander 1, I F McKenzie 1, R C Bennett 1
PMCID: PMC1977294  PMID: 1854611

Abstract

The variation in survival of women with clinically similar breast cancers may lead to difficulty in clinical management so it is important to recognise factors which indicate the prognosis. Immunoperoxidase staining patterns of primary breast tumours using monoclonal antibody NCRC-11 have been shown to relate to overall survival (Ellis et al., 1985) but the results have not been reproducible in other centres. In this study paraffin sections of 483 primary breast cancers were stained with NCRC-11 and 3E1.2 using an immunoperoxidase system. The tumour staining patterns were compared with overall survival using life tables and tested for relative prognostic significance by Cox's multivariate analysis. NCRC-11 related to survival in all 483 cases (chi 2 5.8, P = 0.02) but both antibodies achieved maximum prognostic significance in lymph node negative patients (chi 2 9.4, P less than 0.002 and chi 2 10.7, P less than 0.001) in whom no other factor was more significant. Immunoperoxidase staining patterns produced by monoclonal antibodies NCRC-11 and 3E1.2 are important prognostic factors in breast cancer.

Full text

PDF
124

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angus B., Napier J., Purvis J., Ellis I. O., Hawkins R. A., Carpenter F., Horne C. H. Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11. J Pathol. 1986 Aug;149(4):301–306. doi: 10.1002/path.1711490406. [DOI] [PubMed] [Google Scholar]
  2. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bryan R. M., Mercer R. J., Bennett R. C., Rennie G. C. Prognostic factors in breast cancer and the development of a prognostic index. Br J Surg. 1986 Apr;73(4):267–271. doi: 10.1002/bjs.1800730408. [DOI] [PubMed] [Google Scholar]
  4. Ellis I. O., Bell J., Todd J. M., Williams M., Dowle C., Robins A. R., Elston C. W., Blamey R. W., Baldwin R. W. Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. Br J Cancer. 1987 Sep;56(3):295–299. doi: 10.1038/bjc.1987.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ellis I. O., Hinton C. P., MacNay J., Elston C. W., Robins A., Owainati A. A., Blamey R. W., Baldwin R. W., Ferry B. Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed) 1985 Mar 23;290(6472):881–883. doi: 10.1136/bmj.290.6472.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ellis I. O., Robins R. A., Elston C. W., Blamey R. W., Ferry B., Baldwin R. W. A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology. 1984 May;8(3):501–516. doi: 10.1111/j.1365-2559.1984.tb02360.x. [DOI] [PubMed] [Google Scholar]
  7. Fisher B., Bauer M., Wickerham D. L., Redmond C. K., Fisher E. R., Cruz A. B., Foster R., Gardner B., Lerner H., Margolese R. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983 Nov 1;52(9):1551–1557. doi: 10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  8. Gilchrist K. W., Kalish L., Gould V. E., Hirschl S., Imbriglia J. E., Levy W. M., Patchefsky A. S., Penner D. W., Pickren J., Roth J. A. Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study. Breast Cancer Res Treat. 1985;5(1):3–10. doi: 10.1007/BF01807642. [DOI] [PubMed] [Google Scholar]
  9. Muir I. M., Ellis I. O., Bell J., Robins R. A. NCRC-11 immunoperoxidase staining patterns in breast cancer: interpretive and technical reproducibility. Histopathology. 1987 Nov;11(11):1208–1210. [PubMed] [Google Scholar]
  10. Stacker S. A., Thompson C. H., Sacks N. P., Tjandra J., Lowe M. G., Bishop J., McKenzie I. F. Detection of mammary serum antigen in sera from breast cancer patients using monoclonal antibody 3E1.2. Cancer Res. 1988 Dec 15;48(24 Pt 1):7060–7066. [PubMed] [Google Scholar]
  11. Stacker S. A., Thompson C., Riglar C., McKenzie I. F. A new breast carcinoma antigen defined by a monoclonal antibody. J Natl Cancer Inst. 1985 Nov;75(5):801–811. doi: 10.1093/jnci/75.5.801. [DOI] [PubMed] [Google Scholar]
  12. Stacker S. A., Tjandra J. J., Xing P. X., Walker I. D., Thompson C. H., McKenzie I. F. Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2. Br J Cancer. 1989 Apr;59(4):544–553. doi: 10.1038/bjc.1989.111. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES